跳至主要内容
临床试验/NCT00199537
NCT00199537已完成不适用

Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Lawson Health Research Institute1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2005年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
1

研究概览

简要总结

Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Age of 40 years or greater
  • Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy)
  • Willing and able to consent

排除标准

  • Metastatic disease to bone
  • Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
  • Renal failure (serum creatinine > 200 umol/L)
  • Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
  • Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
  • Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
  • Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
  • Parathyroid disease

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Bone Loss in Men on Androgen Blockade as Adjuvant... | 临床试验